-
Shaun GAO
Equity Partner / Shanghai
-
Tel +86-21-6061-3666
Email shaungao@zhonglun.com
-
Practices
Private Equity & Investment Funds, Hong Kong & Overseas Capital Markets, Cross-border Investment/M&A
-
Industries
Telecommunications & Internet, Information & Intelligence Technology, Pharmaceuticals & Life Sciences
Shaun GAO
Shaun specializes in private equity and venture capital, cross-border mergers and acquisitions, corporate restructuring and offshore capital markets. Since 2005, Shaun worked in the Shanghai Office of two US based international law firms for more than ten years. Working across life sciences and healthcare, IT and telecoms, advertising and broadcasting, clean and renewable energy, education, new media, retailing and franchising, and traditional manufacturing sectors.
Especially, Shaun is one of the “early birds” in PE/VC investment and financing in life sciences and healthcare sector. He led the design of multi-jurisdiction holding structure. He has advised on a number of eye-catching deals, including Innovent, CStone, Hua Medicine, I-Mab, Ocumension, Everest Medicines, GraCell, Transcenta, Abbisko, Genesis MedTech, Zylox-Tonbridge, Edge Medical, InSilico, New Horizen, etc.
Representative Matters
Advised Ocumension on its incubation and inception, each round of equity financing, restructuring and initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited
Advised Everest Medicines on its incubation and inception, each round of equity financing (including its USD 310 million Series C financing that was the highest single round financing in Zhong Lun Bio-tech sector), merger and restructuring and initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited
Advised GraCell on its incubation and inception, multiple rounds of equity financing, red-chip restructuring and initial public offering on NASDAQ
Advised C-Mab on its incubation and inception, each round of equity financing, and trade sale
Advised Cyclone on its multiple rounds of equity financing, including the latest USD 150 million Series C financing that is the highest single round financing in PRC RPA sector
Advised on Lianlian Pay on its restructuring and multiple rounds of equity financing
Honors and Awards
For Individual
Highly Regarded, IFLR1000 2023 - Private Equity
Rising Star Partner, IFLR1000 2022-2023 - Private Equity and Merger and Acquisition
Publications
"When the only certainty is uncertainty - An analysis on VC invetment structure and terms design on pharmaceuticals sector", Zhong Lun Research Center, 2018
Related
-
Deals Related
-
Awards Related
30 Zhong Lun Lawyers from Eight Regions Took Spots in “IFLR1000 China” Regional Ranking
Zhong Lun honored on the “IFLR1000 China” regional ranking.
2024-09-03
-
Bar Admissions/Professional Qualifications
PRC Bar, 2006
-
Education
LL.M., University of Sheffield
LL.B., East China University of Political Science and Law -
Professional Experience
Equity Partner, Zhong Lun Law Firm
Senior Counsel, Katten Muchin Rosenman LLP
Legal Consultant, Troutman Pepper Hamilton Sanders LLP -
Languages
Chinese
English